ResMed FY26 revenue and EPS rise; RBC upgrades price target
ResMed reported FY26 revenue of $5.7B, EPS up 16%, and sleep-device sales gains (Americas +8%, international +13%). The company returned about $1B to shareholders and flagged FY27 upside tied to innovation and digital health; RBC upgraded and raised its price target to $262.